Algenics Signs With Roquette for the Development of an Innovative Microalgae Strain for High Value Industrial Uses.
Press Release
ALGENICS SAS has announced that it has signed a new cooperation contract with the ROQUETTE Group for the development of an innovative microalgae strain capable of producing high levels of a metabolite for high value industrial uses.
The two-year programme is based on the use of ALGENICS’ genetic engineering platform, AlgebiosysTM, and is coupled with the signature of a licensing agreement for use of the technology. The financial terms of the contract have not been disclosed.
“We are delighted to be building on our relationship with the ROQUETTE Group to develop this strain. It will be soon highlighted on an industrial scale,” explained Aude Carlier, CSO of ALGENICS. “The signature of this contract is a tangible example of the strong potential our technology offers for using microalgae in bioproduction,” concluded Morgan Cabigliera, CEO of ALGENICS.
“We are particularly pleased to be embarking on this new project with ALGENICS. The strain that will be developed using AlgebiosysTM technology will quickly help us to extend our range of nutraceuticals, cosmetics and pharmaceuticals derived from microalgae” commented Anne Cortier, Director of the NUTRAHUB® Nutrition and Health research programme at the Roquette Group.
For further information
Contact: Morgan Cabigliera
CEO
Email: contact@algenics.com
Web: www.algenics.com
